Journal Mobile Options
Table of Contents
Vol. 2, No. 3-4, 2005
Issue release date: January 2006
Section title: Structure of SOD1 Mutants: Implications for ALS
Neurodegenerative Dis 2005;2:115–127
(DOI:10.1159/000089616)

Mutant SOD1 Instability: Implications for Toxicity in Amyotrophic Lateral Sclerosis

Tiwari A. · Hayward L.J.
Department of Neurology, University of Massachusetts Medical School, Worcester, Mass., USA

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger (new!)
  • Unrestricted printing, no saving restrictions for personal use
  • Reduced rates with a PPV account
read more

Direct: USD 38.00
Account: USD 26.50

Select

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restriction apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Automatic perpetual access to all articles of the subscribed year(s)
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select


Article / Publication Details

First-Page Preview
Abstract of Structure of SOD1 Mutants: Implications for ALS

Published online: 1/6/2006

Number of Print Pages: 13
Number of Figures: 6
Number of Tables: 0

ISSN: 1660-2854 (Print)
eISSN: 1660-2862 (Online)

For additional information: http://www.karger.com/NDD

Abstract

The biological basis of preferential motor neuron degeneration in amyotrophic lateral sclerosis (ALS) remains incompletely understood, and effective therapies to prevent the lethal consequences of this disorder are not yet available. Since 1993, more than 100 mutant variants of the antioxidant enzyme Cu/Zn superoxide dismutase (SOD1) have been identified in familial ALS. Many studies have sought to distinguish abnormal properties shared by these proteins that may contribute to their toxic effects and cause age-dependent motor neuron loss. Complex networks of cellular interactions and changes associated with aging may link mutant SOD1s and other stresses to motor neuron death in ALS. Our laboratory and collaborators have compared physicochemical properties of biologically metallated wild-type and mutant SOD1 proteins to discern specific vulnerabilities that may be relevant to the mutant toxicity in vivo. X-ray crystal structures obtained from metallated ‘wild-type-like’ (WTL) SOD1 mutants, which retain the ability to bind copper and zinc and exhibit normal specific activity, indicate a native-like structure with only subtle changes to the backbone fold. In contrast, a group of ‘metal-binding region’ (MBR) SOD1 mutants that are deficient in copper and zinc exhibit severe thermal destabilization and structural disorder of conserved loops near the metal-binding sites. A growing body of evidence highlights specific stresses in vivo that may perturb well-folded, metallated SOD1 variants and thereby favor an increased burden of partially unfolded, metal-deficient species. For example, WTL SOD1 mutants are more susceptible than wild-type SOD1 to reduction of the intrasubunit disulfide bond between Cys-57 and Cys-146 at physiological pH and temperature. This bond anchors the disulfide loop to the SOD1 β-barrel and helps to maintain the dimeric configuration of the protein. Cleavage of the disulfide linkage renders the well-folded WTL mutants vulnerable to metal loss and monomerization such that they may resemble the destabilized and locally misfolded MBR mutant species. SOD1 proteins with disordered loops or monomeric structure are expected to be more susceptible to aberrant self-association or detrimental interactions with other cellular constituents. The challenge for future investigations is to relate these abnormal properties of partially unfolded SOD1 to specific mechanisms of toxicity in motor neurons, supporting cells, or target tissues.


Article / Publication Details

First-Page Preview
Abstract of Structure of SOD1 Mutants: Implications for ALS

Published online: 1/6/2006

Number of Print Pages: 13
Number of Figures: 6
Number of Tables: 0

ISSN: 1660-2854 (Print)
eISSN: 1660-2862 (Online)

For additional information: http://www.karger.com/NDD


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Rowland LP, Shneider NA: Amyotrophic lateral sclerosis. N Engl J Med 2001;344:1688–1700.
  2. Marklund S: Distribution of CuZn superoxide dismutase and Mn superoxide dismutase in human tissues and extracellular fluids. Acta Physiol Scand Suppl 1980;492:19–23.
  3. Pardo CA, Xu Z, Borchelt DR, Price DL, Sisodia SS, Cleveland DW: Superoxide dismutase is an abundant component in cell bodies, dendrites, and axons of motor neurons and in a subset of other neurons. Proc Natl Acad Sci USA 1995;92:954–958.
  4. Sturtz LA, Diekert K, Jensen LT, Lill R, Culotta VC: A fraction of yeast Cu,Zn-superoxide dismutase and its metallochaperone, CCS, localize to the intermembrane space of mitochondria. A physiological role for SOD1 in guarding against mitochondrial oxidative damage. J Biol Chem 2001;276:38084–38089.
  5. Okado-Matsumoto A, Fridovich I: Subcellular distribution of superoxide dismutases (SOD) in rat liver: Cu,Zn-SOD in mitochondria. J Biol Chem 2001;276:38388–38393.
  6. Higgins CM, Jung C, Ding H, Xu Z: Mutant Cu,Zn-superoxide dismutase that causes motoneuron degeneration is present in mitochondria in the CNS. J Neurosci 2002;22:RC215.
  7. Higgins CM, Jung C, Xu Z: ALS-associated mutant SOD1G93A causes mitochondrial vacuolation by expansion of the intermembrane space and by involvement of SOD1 aggregation and peroxisomes. BMC Neurosci 2003;4:16.
  8. Pasinelli P, Belford ME, Lennon N, Bacskai BJ, Hyman BT, Trotti D, et al: Amyotrophic lateral sclerosis-associated SOD1 mutant proteins bind and aggregate with Bcl-2 in spinal cord mitochondria. Neuron 2004;43:19–30.
  9. Liu J, Lillo C, Jonsson PA, Vande Velde C, Ward CM, Miller TM, et al: Toxicity of familial ALS-linked SOD1 mutants from selective recruitment to spinal mitochondria. Neuron 2004;43:5–17.
  10. Vijayvergiya C, Beal MF, Buck J, Manfredi G: Mutant superoxide dismutase-1 forms aggregates in the brain mitochondrial matrix of amyotrophic lateral sclerosis mice. J Neurosci 2005;25:2463–2470.
  11. Cleveland DW, Rothstein JD: From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS. Nat Rev Neurosci 2001;2:806–819.
  12. Brown RH Jr, Robberecht W: Amyotrophic lateral sclerosis: pathogenesis. Semin Neurol 2001;21:131–139.
  13. Julien JP: Amyotrophic lateral sclerosis. Unfolding the toxicity of the misfolded. Cell 2001;104:581–591.
  14. Beckman JS, Estevez AG, Crow JR: Superoxide dismutase and the death of motoneurons in ALS. Trends Neurosci 2001;24:S15–S20.
  15. Bruijn LI, Miller TM, Cleveland DW: Unraveling the mechanisms involved in motor neuron degeneration in ALS. Annu Rev Neurosci 2004;27:723–749.
  16. Valentine JS, Doucette PA, Potter SZ: Copper-zinc superoxide dismutase and amyotrophic lateral sclerosis. Annu Rev Biochem 2005; 74:563–593.
  17. Clement AM, Nguyen MD, Roberts EA, Garcia ML, Boillee S, Rule M, et al: Wild-type nonneuronal cells extend survival of SOD1 mutant motor neurons in ALS mice. Science 2003;302:113–117.
  18. Rao SD, Weiss JH: Excitotoxic and oxidative cross-talk between motor neurons and glia in ALS pathogenesis. Trends Neurosci 2004;27:17–23.
  19. Borchelt DR, Lee MK, Slunt HS, Guarnieri M, Xu ZS, Wong PC, et al: Superoxide dismutase-1 with mutations linked to familial amyotrophic lateral sclerosis possesses significant activity. Proc Natl Acad Sci USA 1994;91:8292–8296.
  20. Hoffman EK, Wilcox HM, Scott RW, Siman R: Proteasome inhibition enhances the stability of mouse Cu/Zn superoxide dismutase with mutations linked to familial amyotrophic lateral sclerosis. J Neurol Sci 1996;139:15–20.
  21. Johnston JA, Dalton MJ, Gurney ME, Kopito RR: Formation of high molecular weight complexes of mutant Cu,Zn-superoxide dismutase in a mouse model for familial amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 2000;97:12571–12576.
  22. Durham HD, Roy J, Dong L, Figlewicz DA: Aggregation of mutant Cu/Zn superoxide dismutase proteins in a culture model of ALS. J Neuropathol Exp Neurol 1997;56:523–530.
  23. Koide T, Igarashi S, Kikugawa K, Nakano R, Inuzuka T, Yamada M, et al: Formation of granular cytoplasmic aggregates in COS7 cells expressing mutant Cu/Zn superoxide dismutase associated with familial amyotrophic lateral sclerosis. Neurosci Lett 1998;257:29–32.
  24. Watanabe M, Dykes-Hoberg M, Cizewski Culotta V, Price DL, Wong PC, Rothstein JD: Histological evidence of protein aggregation in mutant SOD1 transgenic mice and in amyotrophic lateral sclerosis neural tissues. Neurobiol Dis 2001;8:933–941.
  25. Wang J, Xu G, Borchelt DR: High molecular weight complexes of mutant superoxide dismutase-1: Age-dependent and tissue-specific accumulation. Neurobiol Dis 2002;9:139–148.
  26. Bruening W, Roy J, Giasson B, Figlewicz DA, Mushynski WE, Durham HD: Up-regulation of protein chaperones preserves viability of cells expressing toxic Cu/Zn-superoxide dismutase mutants associated with amyotrophic lateral sclerosis. J Neurochem 1999;72:693–699.
  27. Shinder GA, Lacourse MC, Minotti S, Durham HD: Mutant Cu/Zn-superoxide dismutase proteins have altered solubility and interact with heat shock/stress proteins in models of amyotrophic lateral sclerosis. J Biol Chem 2001;276:12791–12796.
  28. Batulan Z, Shinder GA, Minotti S, He BP, Doroudchi MM, Nalbantoglu J, et al: High threshold for induction of the stress response in motor neurons is associated with failure to activate HSF1. J Neurosci 2003;23:5789–5798.
  29. Niwa J, Ishigaki S, Hishikawa N, Yamamoto M, Doyu M, Murata S, et al: Dorfin ubiquitylates mutant SOD1 and prevents mutant SOD1-mediated neurotoxicity. J Biol Chem 2002;277:36793–36798.
  30. Miyazaki K, Fujita T, Ozaki T, Kato C, Kurose Y, Sakamoto M, et al: NEDL1, a novel ubiquitin-protein isopeptide ligase for dishevelled-1, targets mutant superoxide dismutase-1. J Biol Chem 2004;279:11327–11335.
  31. Tainer JA, Getzoff ED, Beem KM, Richardson JS, Richardson DC: Determination and analysis of the 2 A-structure of copper, zinc superoxide dismutase. J Mol Biol 1982;160:181–217.
  32. Bertini I, Mangani S, Viezzoli MS: Structure and properties of copper-zinc superoxide dismutases. Adv Inorg Chem 1998;45:127–250.
  33. Forman HJ, Fridovich I: On the stability of bovine superoxide dismutase. The effects of metals. J Biol Chem 1973;248:2645–2649.
  34. Roe JA, Butler A, Scholler DM, Valentine JS, Marky L, Breslauer KJ: Differential scanning calorimetry of Cu,Zn-superoxide dismutase, the apoprotein, and its zinc-substituted derivatives. Biochemistry 1988;27:950–958.
  35. Banci L, Bertini I, Cramaro F, Del Conte R, Rosato A, Viezzoli MS: Backbone dynamics of human Cu,Zn-superoxide dismutase and of its monomeric F50E/G51E/E133Q mutant: The influence of dimerization on mobility and function. Biochemistry 2000;39:9108–9118.
  36. Crow JP, Sampson JB, Zhuang Y, Thompson JA, Beckman JS: Decreased zinc affinity of amyotrophic lateral sclerosis-associated superoxide dismutase mutants leads to enhanced catalysis of tyrosine nitration by peroxynitrite. J Neurochem 1997;69:1936–1944.
  37. Estevez AG, Crow JP, Sampson JB, Reiter C, Zhuang Y, Richardson GJ, et al: Induction of nitric oxide-dependent apoptosis in motor neurons by zinc-deficient superoxide dismutase. Science 1999;286:2498–2500.
  38. Banci L, Bertini I, Cantini F, D’Onofrio M, Viezzoli MS: Structure and dynamics of copper-free SOD: the protein before binding copper. Protein Sci 2002;11:2479–2492.
  39. Banci L, Bertini I, Cramaro F, Del Conte R, Viezzoli MS: Solution structure of Apo Cu,Zn-superoxide dismutase: role of metal ions in protein folding. Biochemistry 2003;42:9543–9553.
  40. Strange RW, Antonyuk S, Hough MA, Doucette PA, Rodriguez JA, Hart PJ, et al: The structure of holo and metal-deficient wild-type human Cu,Zn-superoxide dismutase and its relevance to familial amyotrophic lateral sclerosis. J Mol Biol 2003;328:877–891.
  41. Lamb AL, Torres AS, O’Halloran TV, Rosenzweig AC: Heterodimer formation between superoxide dismutase and its copper chaperone. Biochemistry 2000;39:14720–14727.
  42. Furukawa Y, Torres AS, O’Halloran TV: Oxygen-induced maturation of SOD1: a key role for disulfide formation by the copper chaperone CCS. Embo J 2004;23:2872–2881.
  43. Field LS, Luk E, Culotta VC: Copper chaperones: personal escorts for metal ions. J Bioenerg Biomembr 2002;34:373–379.
  44. Field LS, Furukawa Y, O’Halloran TV, Culotta VC: Factors controlling the uptake of yeast copper/zinc superoxide dismutase into mitochondria. J Biol Chem 2003;278:28052–28059.
  45. Hayward LJ, Rodriguez JA, Kim JW, Tiwari A, Goto JJ, Cabelli DE, et al: Decreased metallation and activity in subsets of mutant superoxide dismutases associated with familial amyotrophic lateral sclerosis. J Biol Chem 2002;277:15923–15931.
  46. Goto JJ, Zhu H, Sanchez RJ, Nersissian A, Gralla EB, Valentine JS, et al: Loss of in vitro metal ion binding specificity in mutant copper-zinc superoxide dismutases associated with familial amyotrophic lateral sclerosis. J Biol Chem 2000;275:1007–1014.
  47. Lyons TJ, Liu H, Goto JJ, Nersissian A, Roe JA, Graden JA, et al: Mutations in copper-zinc superoxide dismutase that cause amyotrophic lateral sclerosis alter the zinc binding site and the redox behavior of the protein. Proc Natl Acad Sci USA 1996;93:12240–12244.
  48. Steinkuhler C, Sapora O, Carri MT, Nagel W, Marcocci L, Ciriolo MR, et al: Increase of Cu,Zn-superoxide dismutase activity during differentiation of human K562 cells involves activation by copper of a constantly expressed copper-deficient protein. J Biol Chem 1991;266:24580–24587.
  49. Petrovic N, Comi A, Ettinger MJ: Identification of an apo-superoxide dismutase (Cu,Zn) pool in human lymphoblasts. J Biol Chem 1996;271:28331–28334.
  50. Bartnikas TB, Gitlin JD: Mechanisms of biosynthesis of mammalian copper/zinc superoxide dismutase. J Biol Chem 2003;278:33602–33608.
  51. Rodriguez JA, Valentine JS, Eggers DK, Roe JA, Tiwari A, Brown RH Jr, et al: Familial amyotrophic lateral sclerosis-associated mutations decrease the thermal stability of distinctly metallated species of human copper/zinc superoxide dismutase. J Biol Chem 2002;277:15932–15937.
  52. Potter SZ, Valentine JS: The perplexing role of copper-zinc superoxide dismutase in amyotrophic lateral sclerosis (Lou Gehrig’s disease). Biol Inorg Chem 2003;8:373–380.
  53. Liochev SI, Chen LL, Hallewell RA, Fridovich I: Superoxide-dependent peroxidase activity of H48Q: a superoxide dismutase variant associated with familial amyotrophic lateral sclerosis. Arch Biochem Biophys 1997;346:263–268.
  54. Lindberg MJ, Tibell L, Oliveberg M: Common denominator of Cu/Zn superoxide dismutase mutants associated with amyotrophic lateral sclerosis: decreased stability of the apo state. Proc Natl Acad Sci USA 2002;99:16607–16612.
  55. Lynch SM, Boswell SA, Colon W: Kinetic stability of Cu/Zn superoxide dismutase is dependent on its metal ligands: implications for ALS. Biochemistry 2004;43:16525–16531.
  56. Tiwari A, Hayward LJ: Familial amyotrophic lateral sclerosis mutants of copper/zinc superoxide dismutase are susceptible to disulfide reduction. J Biol Chem 2003;278:5984–5992.
  57. Furukawa Y, O’Halloran TV: Amyotrophic lateral sclerosis mutations have the greatest destabilizing effect on the apo- and reduced form of SOD1, leading to unfolding and oxidative aggregation. J Biol Chem 2005;280:17266–17274.
  58. Hwang C, Sinskey AJ, Lodish HF: Oxidized redox state of glutathione in the endoplasmic reticulum. Science 1992;257:1496–1502.
  59. Cardoso RM, Thayer MM, DiDonato M, Lo TP, Bruns CK, Getzoff ED, et al: Insights into Lou Gehrig’s disease from the structure and instability of the A4V mutant of human Cu,Zn-superoxide dismutase. J Mol Biol 2002;324:247–256.
  60. Hough MA, Grossmann JG, Antonyuk SV, Strange RW, Doucette PA, Rodriguez JA, et al: Dimer destabilization in superoxide dismutase may result in disease-causing properties: structures of motor neuron disease mutants. Proc Natl Acad Sci USA 2004;101:5976–5981.
  61. Arnesano F, Banci L, Bertini I, Martinelli M, Furukawa Y, O’Halloran TV: The unusually stable quaternary structure of human Cu,Zn-superoxide dismutase-1 is controlled by both metal occupancy and disulfide status. J Biol Chem 2004;279:47998–48003.
  62. Lindberg MJ, Normark J, Holmgren A, Oliveberg M: Folding of human superoxide dismutase: disulfide reduction prevents dimerization and produces marginally stable monomers. Proc Natl Acad Sci USA 2004;101:15893–15898.
  63. Doucette PA, Whitson LJ, Cao X, Schirf V, Demeler B, Valentine JS, et al: Dissociation of human copper-zinc superoxide dismutase dimers using chaotrope and reductant. Insights into the molecular basis for dimer stability. J Biol Chem 2004;279:54558–54566.
  64. Rodriguez JA, Shaw BF, Durazo A, Sohn SH, Doucette PA, Faull KF, et al: Destabilization of Cu-Zn superoxide dismutase (SOD1) apoprotein is insufficient to explain neurodegenerative effects of mutations that cause amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 2005;102:10516–10521.
  65. Elam JS, Taylor AB, Strange R, Antonyuk S, Doucette PA, Rodriguez JA, et al: Amyloid-like filaments and water-filled nanotubes formed by SOD1 mutant proteins linked to familial ALS. Nat Struct Biol 2003;10:461–467.
  66. Tiwari A, Xu Z, Hayward L: Aberrantly increased hydrophobicity shared by mutants of Cu/Zn superoxide dismutase in familial amyotrophic lateral sclerosis. J Biol Chem 2005;280:29771–29779.
  67. Watanabe M, Dykes-Hoberg M, Culotta VC, Price DL, Wong PC, Rothstein JD: Histological evidence of protein aggregation in mutant SOD1 transgenic mice and in amyotrophic lateral sclerosis neural tissues. Neurobiol Dis 2001;8:933–941.
  68. Jonsson PA, Ernhill K, Andersen PM, Bergemalm D, Brannstrom T, Gredal O, et al: Minute quantities of misfolded mutant superoxide dismutase-1 cause amyotrophic lateral sclerosis. Brain 2004;127:73–88.
  69. Deng HX, Hentati A, Tainer JA, Iqbal Z, Cayabyab A, Hung WY, et al: Amyotrophic lateral sclerosis and structural defects in Cu,Zn-superoxide dismutase. Science 1993;261:1047–1051.
  70. Banci L, Bertini I, Cramaro F, Del Conte R, Viezzoli MS: The solution structure of reduced dimeric copper zinc superoxide dismutase. The structural effects of dimerization. Eur J Biochem 2002;269:1905–1915.
  71. Hart PJ, Liu H, Pellegrini M, Nersissian AM, Gralla EB, Valentine JS, et al: Subunit asymmetry in the three-dimensional structure of a human CuZnSOD mutant found in familial amyotrophic lateral sclerosis. Protein Sci 1998;7:545–555.
  72. DiDonato M, Craig L, Huff ME, Thayer MM, Cardoso RM, Kassmann CJ, et al: ALS mutants of human superoxide dismutase form fibrous aggregates via framework destabilization. J Mol Biol 2003;332:601–615.
  73. Shipp EL, Cantini F, Bertini I, Valentine JS, Banci L: Dynamic properties of the G93A mutant of copper-zinc superoxide dismutase as detected by NMR spectroscopy: implications for the pathology of familial amyotrophic lateral sclerosis. Biochemistry 2003;42:1890–1899.
  74. Antonyuk S, Elam JS, Hough MA, Strange RW, Doucette PA, Rodriguez JA, et al: Structural consequences of the familial amyotrophic lateral sclerosis SOD1 mutant His46Arg. Protein Sci 2005;14:1201–1213.
  75. Stathopulos PB, Rumfeldt JA, Scholz GA, Irani RA, Frey HE, Hallewell RA, et al: Cu/Zn superoxide dismutase mutants associated with amyotrophic lateral sclerosis show enhanced formation of aggregates in vitro. Proc Natl Acad Sci USA 2003;100:7021–7026.
  76. Rakhit R, Crow JP, Lepock JR, Kondejewski LH, Cashman NR, Chakrabartty A: Monomeric Cu,Zn-superoxide dismutase is a common misfolding intermediate in the oxidation models of sporadic and familial amyotrophic lateral sclerosis. J Biol Chem 2004;279:15499–15504.